Philips 2007 Annual Report Download - page 85

Philips Annual Report 2007 91
The generation of (white) light with highly controlled color
characteristics is a key enabling factor for solid-state lighting
to enter the general lighting market. Lumiramic technology
enables high-volume production of white LEDs with a very
specic correlated color temperature, ensuring luminaire-to-
luminaire consistency.
workow for high-quality scans. For CT, a totally new
hardware architecture has been developed, including
an air-bearing gantry and new x-ray optics, allowing
extremely high-speed multiple-slice scanning, which
yields much sharper heart images. In solid-state lighting,
Lumiramics technology has been transferred to Philips
Lighting, providing the business with a breakthrough in
color consistency for white LED products, a key
component in the solid-state lighting revolution.
Generating patents
Philips led approximately 1,625 patents in 2007.
Currently, Philips is in the process of reshaping its
intellectual property portfolio in line with its new strategic
focus on Healthcare, Lighting and Consumer Lifestyle.
Incubating new businesses
The Philips Incubators are separate business units within
Corporate Technologies. In 2007 there was public
presence for 3D Solutions, amBX, Handshake Solutions,
Lumalive, Content Identication, Beatbrew, Care Servant
and Handheld Diagnostics, including a commercialization
agreement with Cozart on drugs-of-abuse testing.
The combined incubator pipelines contain more than
25 ventures. To ensure more effective management
of the ventures in the pipeline, Bell-Mason stage gating
was introduced in 2006, with preceding phases added
in Philips Research. In 2007, more than 500 people across
Philips were trained in this methodology.
Stimulating end-user focus
Philips has introduced the Value Proposition House
methodology to capture end-user insights and create
meaningful innovations. Marketing, supply management
and R&D have worked closely together to create a
process for value propositions and how to translate
them into successful innovations.
2007 nancial performance
Corporate Technologies’ EBITA improved to a loss
of EUR 76 million, compared to a loss of EUR 91 million
in 2006, which included a EUR 31 million gain on the sale
of CryptoTec. The improvement in EBITA was largely
attributable to an increase in income from intellectual
property and cost efciencies at Research, partly offset
by increased investment in the Healthcare and Lifestyle
Incubators and in research activities in emerging markets.
In 2007, Corporate Technologies recognized a gain on
the sale of TASS (EUR 6 million), which was divested in
the rst quarter.
Strategy and 2008 objectives
Corporate Technologies’ strategy for 2008 and beyond
will focus on:
Developing advanced technologies and applications •
to create meaningful innovations
Generating patents to protect these innovations, •
particularly in key areas of growth
Incubating new businesses as a driver of sustainable •
growth
Improving innovation effectiveness by stimulating •
end-user focus and cross-functional collaboration
with marketing and supply management
Establishing closer links to the business sectors by •
reinforcing the account management function. This will
ensure sharing of user insights, roadmap continuity and
awareness of business options.
98 Risk management 112 Our leadership 116 Report of the Supervisory Board 126 Financial Statements